Latest fiscal year 2020 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2020, NextCure, Inc. reported revenue of $22M. Operating margin was -184.2% and net margin -163.6%, on a free-cash-flow margin of -232.8% with capital expenditure at 31.9% of revenue. Every figure is computed directly from NXTC's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2020 | $22M | -184.2% | -163.6% |
How does NXTC compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.